Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 16, 2022; 10(8): 2468-2473
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2468
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2468
Table 1 C-reactive protein and liver test levels (D0: Day when escitalopram was withdrawn)
| Date | C-reactive protein (mg/L) | Total bilirubin (µmol/L) | Conjugated bilirubin (µmol/L) | Unconjugated bilirubin (µmol/L) | Alanine transa-minase (IU/L) |
| D - 22 | < 5.00 | 4 | |||
| D0 | 8.20 | 101 | 65 | 36 | 80 |
| D + 1 | 7.80 | 109 | 66 | 43 | 77 |
| D + 3 | 15.00 | 117 | 69 | 48 | 72 |
| D + 4 | 13.90 | 115 | 71 | 44 | 69 |
| D + 16 | 84 | 46 | 38 | 58 | |
| D + 20 | 50 | 24 | 26 | ||
| D + 29 | 6.90 | 25 | 11 | 14 | 43 |
- Citation: Wabont G, Ferret L, Houdre N, Lepied A, Bene J, Cousein E. Escitalopram-induced hepatitis: A case report. World J Clin Cases 2022; 10(8): 2468-2473
- URL: https://www.wjgnet.com/2307-8960/full/v10/i8/2468.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i8.2468